CCCC
C4 Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$393.62M
P/E Ratio
—
EPS
$-1.10
Beta
2.78
52W High
$3.95
52W Low
$1.21
50-Day MA
$2.90
200-Day MA
$2.53
Dividend Yield
—
Profit Margin
-297.80%
Forward P/E
—
PEG Ratio
—
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | $34.86M |
| Gross Profit (TTM) | $25.88M |
| EBITDA | $-101.20M |
| Operating Margin | -451.60% |
| Return on Equity | -48.30% |
| Return on Assets | -19.90% |
| Revenue/Share (TTM) | $0.36 |
| Book Value | $2.25 |
| Price-to-Book | 1.68 |
| Price-to-Sales (TTM) | 11.29 |
| EV/Revenue | 6.21 |
| EV/EBITDA | -0.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -15.00% |
| Shares Outstanding | $110.57M |
| Float | $79.64M |
| % Insiders | 1.13% |
| % Institutions | 76.66% |
Historical Volatility
HV 10-Day
110.61%
HV 20-Day
92.71%
HV 30-Day
81.95%
HV 60-Day
97.63%
HV Rank
27.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($11.57 target)
1
Strong Buy7
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026